Related references
Note: Only part of the references are listed.Human Papillomavirus Infection and Reinfection in Adult Women: the Role of Sexual Activity and Natural Immunity
Helen Trottier et al.
CANCER RESEARCH (2010)
Molecular and structural characterization of the L1 virus-like particles that are used as vaccine antigens in Cervarix™, the AS04-adjuvanted HPV-16 and-18 cervical cancer vaccine
Michel Deschuyteneer et al.
HUMAN VACCINES (2010)
Differential regulation of TLR4 expression in human B cells and monocytes
Lisa M. Ganley-Leal et al.
MOLECULAR IMMUNOLOGY (2010)
Sustained efficacy and immunogenicity of the HPV-16/18 ASO4-adjuvanted vaccine up to 7.3 years in young adult women
N. De Carvalho et al.
VACCINE (2010)
Regulation and Function of NF-kappa B Transcription Factors in the Immune System
Sivakumar Vallabhapurapu et al.
ANNUAL REVIEW OF IMMUNOLOGY (2009)
Safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine for cervical cancer prevention A pooled analysis of 11 clinical trials
Dominique Descamps et al.
HUMAN VACCINES (2009)
Comparison of the immunogenicity and safety of Cervarix™ and Gardasil® human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years
Mark H. Einstein et al.
HUMAN VACCINES (2009)
AS04, an Aluminum Salt- and TLR4 Agonist-Based Adjuvant System, Induces a Transient Localized Innate Immune Response Leading to Enhanced Adaptive Immunity
Arnaud M. Didierlaurent et al.
JOURNAL OF IMMUNOLOGY (2009)
Randomized, Double-Blind, Phase 2a Trial of Falciparum Malaria Vaccines RTS,S/AS01B and RTS,S/AS02A in Malaria-Naive Adults: Safety, Efficacy, and Immunologic Associates of Protection
Kent E. Kester et al.
JOURNAL OF INFECTIOUS DISEASES (2009)
Immune dysregulation in human immunodeficiency virus infection: know it, fix it, prevent it?
A. Boasso et al.
JOURNAL OF INTERNAL MEDICINE (2009)
Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women
J. Paovonen et al.
LANCET (2009)
Immunogenicity and tolerability of an HPV-16/18 AS04-adjuvanted prophylactic cervical cancer vaccine in women aged 15-55 years
Tino F. Schwarz et al.
VACCINE (2009)
Safety and immunogenicity of a new hepatitis B vaccine for the protection of patients with renal insufficiency including pre-haemodialysis and haemodialysis patients
Jiri Beran
EXPERT OPINION ON BIOLOGICAL THERAPY (2008)
Immune response to human papillomavirus after prophylactic vaccination with AS04-adjuvanted HPV-16/18 vaccine: Improving upon nature
Tino F. Schwarz et al.
GYNECOLOGIC ONCOLOGY (2008)
Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial
Susan P. Buchbinder et al.
LANCET (2008)
Epidemiology and Natural History of Human Papillomavirus Infections and Type-Specific Implications in Cervical Neoplasia
F. Xavier Bosch et al.
VACCINE (2008)
Analysis of adverse events of potential autoimmune aetiology in a large integrated safety database of AS04 adjuvanted vaccines
Thomas Verstraeten et al.
VACCINE (2008)
MF59 is a safe and potent vaccine adjuvant for flu Vaccines in humans: What did we learn during its development?
D. T. O'Hagan et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2007)
Historical comparisons of morbidity and mortality for vaccine-preventable diseases in the United States
Sandra W. Roush et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2007)
Influenza virosomes as a combined vaccine carrier and adjuvant system for prophylactic and therapeutic immunizations
Christian Moser et al.
EXPERT REVIEW OF VACCINES (2007)
GlaxoSmithKline Adjuvant systems in vaccines: concepts, achievements and perspectives
Nathalie Garcon et al.
EXPERT REVIEW OF VACCINES (2007)
Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine:: a randomised controlled trial
Isabel Leroux-Roels et al.
LANCET (2007)
The perfect mix: recent progress in adjuvant research
Bruno Guy
NATURE REVIEWS MICROBIOLOGY (2007)
Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women:: an interim analysis of a phase III double-blind, randomised controlled trial
Jorma Paavonen et al.
LANCET (2007)
The vaccine adjuvant monophosphoryl lipid A as a TRIF-biased agonist of TLR4
Veronica Mata-Haro et al.
SCIENCE (2007)
Immunosenescence: Role and measurement in influenza vaccine response among the elderly
Paul V. Targonski et al.
VACCINE (2007)
Comparison of cervical and blood T-cell responses to human papillomavirus-16 in women with human papillomavirus-associated cervical intraepithelial neoplasia
Jo-Ann S. Passmore et al.
IMMUNOLOGY (2006)
Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only
Sandra L. Giannini et al.
VACCINE (2006)
Sustained efficacy up to 4-5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial
DM Harper et al.
LANCET (2006)
How bacteria and their products provide clues to vaccine and adjuvant development
G Dougan et al.
VACCINE (2006)
Toll-like receptor stimulation as a third signal required for activation of human naive B cells
CR Ruprecht et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2006)
Pathogen recognition and innate immunity
S Akira et al.
CELL (2006)
Translating innate immunity into immunological memory: Implications for vaccine development
B Pulendran et al.
CELL (2006)
The carcinogenicity of human papillornavirus types reflects viral evolution
M Schiffman et al.
VIROLOGY (2005)
B lymphocyte activation by human papillomavirus-like particles directly induces Ig class switch recombination via TLR4-MyD88
RC Yang et al.
JOURNAL OF IMMUNOLOGY (2005)
Vaccines: past, present and future
SA Plotkin
NATURE MEDICINE (2005)
Global cancer statistics, 2002
DM Parkin et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2005)
Against which human papillomavirus types shall we vaccinate and screen?: The international perspective
N Muñoz et al.
INTERNATIONAL JOURNAL OF CANCER (2004)
Safety and immunogenicity profile of an experimental hepatitis B vaccine adjuvanted with AS04
G Boland et al.
VACCINE (2004)
Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial
DM Harper et al.
LANCET (2004)
Natural history of human papillomavirus type 16 virus-like particle antibodies in young women
GYF Ho et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2004)
Immunological foundations to the quest for new vaccine adjuvants
N Burdin et al.
BIODRUGS (2004)
The toll-like receptor repertoire of human B lymphocytes: inducible and selective expression of TLR9 and TLR10 in normal and transformed cells
E Bourke et al.
BLOOD (2003)
A role for Toll-like receptors in acquired immunity: up-regulation of TLR9 by BCR triggering in naive B cells and constitutive expression in memory B cells
NL Bernasconi et al.
BLOOD (2003)
Epidemiologic classification of human papillomavirus types associated with cervical cancer
N Muñoz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Human papillomavirus immortalization and transformation functions
K Münger et al.
VIRUS RESEARCH (2002)
The danger model: A renewed sense of self
P Matzinger
SCIENCE (2002)
A prospective study of human papillomavirus (HPV) type 16 DNA detection by polymerase chain reaction and its association with acquisition and persistence of other HPV types
KL Liaw et al.
JOURNAL OF INFECTIOUS DISEASES (2001)
Toll-like receptor 4, but not toll-like receptor 2, is a signaling receptor for Escherichia and Salmonella lipopolysaccharides
RI Tapping et al.
JOURNAL OF IMMUNOLOGY (2000)
Vaccines against intracellular infections requiring cellular immunity
RA Seder et al.
NATURE (2000)
Share Paper
